Vertex will utilize Orna's novel and proprietary LNP delivery solutions to enhance efforts in developing next generation gene editing therapies for patients with Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).

Under the terms of the agreement, Orna will receive upfront payments of $65 million, including an investment in the form of a convertible note, and is eligible to receive up to $635 million based upon the achievement of specified pre-clinical, research, development, regulatory and commercial milestones related to SCD/TDT products.

Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications.